Inuzuka Hiroyuki, Fukushima Hidefumi, Shaik Shavali, Wei Wenyi
Oncotarget. 2010 Nov;1(7):685-690. doi: 10.18632/oncotarget.202.
The Mdm2/p53 pathway is compromised in more than 50% of all human cancers, therefore it is an intensive area of research to understand the upstream regulatory pathways governing Mdm2/p53 activity. Mdm2 is frequently overexpressed in human cancers while the molecular mechanisms underlying the timely destruction of Mdm2 remain unclear. We recently reported that Casein Kinase I phosphorylates Mdm2 at multiple sites to trigger Mdm2 interaction with, and subsequent ubiquitination and destruction by the SCF(β-TRCP) E3 ubiquitin ligase. We also demonstrated that the E3 ligase activity-deficient Mdm2 was still unstable in the G1 phase and could be efficiently degraded by SCF(β-TRCP). Thus our finding expands the current knowledge on how Mdm2 is tightly regulated by both self- and SCF(β-TRCP)-dependent ubiquitination to control p53 activity in response to stress. It further indicates that loss of β-TRCP or Casein Kinase I function contributes to elevated Mdm2 expression that is frequently found in various types of tumors.
在超过50%的人类癌症中,Mdm2/p53信号通路存在缺陷,因此,了解调控Mdm2/p53活性的上游调控通路是一个深入研究的领域。Mdm2在人类癌症中经常过度表达,而Mdm2及时降解的分子机制仍不清楚。我们最近报道,酪蛋白激酶I在多个位点磷酸化Mdm2,以触发Mdm2与SCF(β-TRCP) E3泛素连接酶的相互作用,随后发生泛素化和降解。我们还证明,E3连接酶活性缺陷的Mdm2在G1期仍然不稳定,并且可以被SCF(β-TRCP)有效降解。因此,我们的发现扩展了目前关于Mdm2如何通过自身和SCF(β-TRCP)依赖的泛素化被严格调控以响应应激控制p53活性的知识。它进一步表明,β-TRCP或酪蛋白激酶I功能的丧失导致Mdm2表达升高,这在各种类型的肿瘤中经常出现。